East Africa Pharma Biotech Conference 2023 C TT Communications
12.09.2024

East Africa Pharma and Biotech Conference 2024

The second East Africa Pharma and Biotech Conference is taking place from 17 to 18 September 2024 in Kigali, Rwanda

The second East Africa Pharma and Biotech Conference is taking place from 17 to 18 September 2024 at the Kigali Convention Centre in Rwanda. Invest for Jobs supports the Government of Rwanda, represented by the Rwanda Biomedical Centre (RBC) and the Africa Centres for Disease Control and Prevention (Africa CDC) in the realisation of this conference.

The conference aims to strengthen the network among experts from industry, politics, academia, civil society and development cooperation, create a peer group and leverage experiences for the continuous development of the pharma and biotech sector in the region.

The conference will concentrate on the current pharma and biotech landscape in East Africa, including ongoing initiatives in the countries. Moreover, attendees will be directed towards market opportunities in the region. 

With a growing population and increasing prevalence of diseases, East Africa is taking significant steps to strengthen its pharmaceutical and biotechnological manufacturing capabilities. The region currently depends on imports, but local initiatives are rapidly gaining momentum to reduce this reliance and foster sustainable, homegrown solutions.

East African countries have recognised the potential of pharmaceutical and biotechnological manufacturing for public health and sustainable economic growth in the region. With a combined market size of more than $4 billion, East Africa offers a significant opportunity for growth in the pharmaceutical and biotechnological sectors, further supported by continental efforts such as the African Pooled Procurement Mechanism (APPM).

To harness this potential, East African countries are creating supportive ecosystems that support pharmaceutical and biotechnological manufacturing. These initiatives include workforce development, regulatory strengthening, entrepreneurship, and infrastructure development, among others. Rwanda is leading the charge with the region’s first acceleration and skills development hub, while the African Medicines Agency (AMA) and other regulatory bodies continue to harmonise policies and standards.

For more information about the event and agenda visit East Africa Pharma & Biotech Conference Website or contact rwanda@invest-for-jobs.com.

Contact

We are looking forward to hearing from you

Under the Invest for Jobs brand, the German Federal Ministry for Economic Cooperation and Development (BMZ) has put together a package of measures to support German, European and African companies in investment activities that have a high impact on employment in Africa. The Special Initiative "Decent Work for a Just Transition" – the official title – offers comprehensive advice, contacts and financial support to overcome investment barriers. The development objective is to work together with companies to create up to 100,000 good jobs and to improve working conditions and social protection in its African partner countries.

Partner countries: Côte d’Ivoire, Egypt, Ethiopia, Ghana, Morocco, Rwanda, Senegal and Tunisia.

Find out more about our services for companies, universities, chambers and associations: https://invest-for-jobs.com/en/offers

at least 300 characters
at least 300 characters
at least 300 characters
at least 300 characters
at least 300 characters
Drag and drop files here or click to upload

    Please check that your enquiry does not match any of the other drop-down options. If so, please click on this option and enter all the required information. Please note that we can only process enquiries that contain all the necessary information.

    Please refer to the Data Protection Statement for information about your rights and options for withdrawing your consent.

    Press contact

    Phone: +49 30 / 18 535-28 70 oder -24 51

    Fax: +49 30 / 18 535-25 95

    E-Mail: presse@bmz.bund.de

    Please understand that the Press Office only answers questions from journalists.